Topline data: Zasocitinib outperforms deucravacitinib for plaque psoriasis

Zasocitinib outperformed deucravacitinib for the treatment of patients with moderate to severe plaque psoriasis, according to topline data. As Healio previously reported, zasocitinib (Takeda) is an investigational, highly selective oral tyrosine kinase 2 (TYK2) inhibitor that blocks interleukin-23 and other pathways driving psoriasis. In the phase 3, head-to-head trial, researchers found that